Displaying drugs 15076 - 15100 of 15774 in total
VXM01
Investigational
KAHR-102
KAHR-102 is a dual signaling protein fusing cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to the Fas-ligand (FasL).
Investigational
ERC-1671
Investigational
pM-81
Investigational
MK-0482
MK-0482 is a novel humanized IgG4 monoclonal antibody targeting the immunoglobulin-like transcript (ILT) 3.
Investigational
MK-4830
MK-4830 is a monoclonal antibody that targets the myeloid-specific immunoglobulin-like transcript (ILT) 4 receptor.
Investigational
ETBX-011
ETBX-011 is a cancer vaccine used to treat patients with cancers that express carcinoembryonic antigen (CEA).
Investigational
Interleukin-15, human recombinant
Investigational
Odetiglucan
Investigational
Incomplete Freund's adjuvant
Investigational
BI-765063
BI-765063 is a humanized IgG4 monoclonal antibody antagonist of signal regulatory protein α (SIRPα).
Investigational
Vidutolimod
Vidutolimod is a Toll-like receptor 9 (TLR9) agonist. It is an investigational cancer vaccine.
Investigational
RO7502175
Investigational
UCPVax
Investigational
GEN-001
Investigational
MRx0518
Investigational
XmAb24306
XmAb24306 is an investigational cancer immunotherapy. It is a heterodimeric interleukin (IL)-15/IL-15-receptor alpha (IL-15Ra) complex fused to a bispecific Fc domain.
Investigational
ETBX-021
Investigational
ETBX-061
Investigational
GI-6301
Investigational
SynOV1.1
SynOV1.1 is an investigational cancer immunotherapy developed by SyngenTech. It is a recombinant oncolytic adenovirus, controlled by synthetic gene circuit, encoding the human immunostimulating factor cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF). SynOV1.1 is under investigation in clinical trial NCT04612504 (Synov1.1 Intratumoral Injection Study).
Investigational
IO-202
IO-202 is a first-in-class antibody targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) member 4 (LILRB4). It is being investigated in cancers.
Investigational
PF-04856884
PF-04856884 or CVX-060 is a selective angiopoietin (Ang)-2 inhibitor. It is under investigation in clinical trial NCT01441414 (PF-04856884 (CVX-060) in Combination With Axitinib in Patients With Previously Treated Metastatic Renal Cell Carcinoma).
Investigational
Displaying drugs 15076 - 15100 of 15774 in total